The Latest Cardiac and Vascular News
Bonfiglio is known for raising capital, building start-ups, and leading successful biotech companies as CEO and COO. LAS VEGAS, March 23, 2023 /PRNewswire/ — JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of […]
Issuance of U.S. Patent 11,247,902 B2 Further Bolsters JanOne Inc.’s Intellectual Patent Portfolio LAS VEGAS, June 7, 2022 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that a patent was […]
JanOne’s management is encouraged regarding Recent Discussions on Potential Phase 2b Trial Endpoints and Possible Regulatory Routes for JAN101 as Treatment for Peripheral Artery Disease (PAD) LAS VEGAS, Sept. 28, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company that focuses on the development […]
CPC to Manage Planning, Organization, and Day-to-Day Execution of the Trial LAS VEGAS, July 22, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that […]
Company Fully Prepared to Commence Phase 2b Trials of JAN101 for Peripheral Artery Disease (PAD) as Soon as New Protocol is Approved by the FDA LAS VEGAS, June 23, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions […]
Global Contract Research Organization (CRO) Avania to Manage All Regulatory Affairs in Connection with JanOne’s Phase 2b Trial Preparedness and Execution LAS VEGAS, June 22, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain […]
Successfully Completes Initial Batch Production of JAN101, Demonstrating CGMP-scale Production Capabilities LAS VEGAS, June 8, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the […]
Successful disposition will facilitate continued strategic focus on high-value late-stage biopharma asset JAN101 for the treatment of peripheral artery disease (PAD) LAS VEGAS, Feb. 25, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain […]
Net proceeds will help support planning of clinical trials for JAN101, the company’s lead drug candidate LAS VEGAS, Feb. 2, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving […]
LAS VEGAS, Jan. 29, 2021 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and […]
